| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
Departments of1 Cancer Biology, 2 Public Health Sciences, and 3 Radiation Oncology, 4 Urology, and 5 Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, and 6 Department of Biochemistry, The Johns Hopkins University, Baltimore, Maryland
Prostate cancer (CaP) is the most commonly diagnosed non-skin cancer and the second leading cause of cancer death in American men. The etiology of CaP is not fully understood. Because most of the DNA adducts generated by some CaP-related carcinogens, including polycyclic aromatic hydrocarbons, heterocyclic amines, and pesticides, are removed by the nucleotide excision repair (NER) pathway, we pilot tested the hypothesis that CaP is associated with deficient NER capacity (NERC), measured by a plasmid-based host reactivation assay. Using cryopreserved lymphocytes collected in an ongoing, clinic-based case-control study, our results showed that the mean NERC was significantly lower (P = 0.03) in 140 cases (mean ± SD, 8.06 ± 5.17) than in 96 controls (9.64 ± 5.49). There was a significant association between below-median NERC and CaP risk: odds ratio (OR), 2.14; 95% confidence interval (CI), 1.19–3.86, after adjustment for age, race/ethnicity, smoking history, benign prostatic hyperplasia, and family history. This association was stronger in younger (<60 years of age) subjects (OR, 3.98; 95% CI, 1.13–14.02) compared with older (
60) subjects (OR, 1.74; 95% CI, 0.90–3.37). When we stratified NERC values by quartiles of controls, there was a significant dose-dependent association between lower NERC and elevated CaP risk (p test for linear trend, 0.01). Compared with the highest quartile of NERC as the referent group, the adjusted ORs for the 75th, 50th, and 25th quartiles were: 1.09 (95% CI, 0.46–2.59); 1.81 (95% CI, 0.77–4.27); and 2.63 (95% CI, 1.17–5.95), respectively. This pilot study is the first direct evidence associating deficient NERC with human CaP risk.
This article has been cited by other articles:
|
|
 |
|
  J. Zabaleta, L. J. Su, H.-Y. Lin, R. A. Sierra, M. C. Hall, A. O. Sartor, P. E. Clark, J. J. Hu, and A. C. Ochoa Cytokine genetic polymorphisms and prostate cancer aggressiveness Carcinogenesis, August 1, 2009; 30(8): 1358 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Xu, A. S. Kibel, J. J. Hu, A. R. Turner, K. Pruett, S. L. Zheng, J. Sun, S. D. Isaacs, K. E. Wiley, S.-T. Kim, et al. Prostate Cancer Risk Associated Loci in African Americans Cancer Epidemiol. Biomarkers Prev., July 1, 2009; 18(7): 2145 - 2149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhao, L.-E Wang, D. Li, R. M. Chamberlain, E. M. Sturgis, and Q. Wei Genotypes and haplotypes of ERCC1 and ERCC2/XPD genes predict levels of benzo[a]pyrene diol epoxide-induced DNA adducts in cultured primary lymphocytes from healthy individuals: a genotype-phenotype correlation analysis Carcinogenesis, August 1, 2008; 29(8): 1560 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hopkins, D. W. Cescon, D. Tse, P. Bradbury, W. Xu, C. Ma, P. Wheatley-Price, J. Waldron, D. Goldstein, F. Meyer, et al. Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 490 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Rybicki, C. Neslund-Dudas, C. H. Bock, A. Rundle, A. T. Savera, J. J. Yang, N. L. Nock, and D. Tang Polycyclic Aromatic Hydrocarbon-DNA Adducts in Prostate and Biochemical Recurrence after Prostatectomy Clin. Cancer Res., February 1, 2008; 14(3): 750 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Waters, S. Shen, H. Xu, S. S. Kengeri, D. M. Cooley, E. C. Chiang, Y. Chen, D. Schlittler, C. Oteham, G. F. Combs Jr., et al. Noninvasive Prediction of Prostatic DNA Damage by Oxidative Stress Challenge of Peripheral Blood Lymphocytes Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1906 - 1910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sussman DNA repair capacity of zebrafish PNAS, August 14, 2007; 104(33): 13379 - 13383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wang, Q. Wei, Q. Shi, Z. Guo, Y. Qiao, and M. R. Spitz A modified host-cell reactivation assay to measure repair of alkylating DNA damage for assessing risk of lung adenocarcinoma Carcinogenesis, July 1, 2007; 28(7): 1430 - 1436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Liu, W. Zhou, B. Y. Yeap, L. Su, J. C. Wain, J. M. Poneros, N. S. Nishioka, T. J. Lynch, and D. C. Christiani XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk Carcinogenesis, June 1, 2007; 28(6): 1254 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Lockett, M.C. Hall, P. E. Clark, S.-C. Chuang, B. Robinson, H.-Y. Lin, L.J. Su, and J. J. Hu DNA damage levels in prostate cancer cases and controls Carcinogenesis, June 1, 2006; 27(6): 1187 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Lockett, M. C. Hall, J. Xu, S. L. Zheng, M. Berwick, S.-C. Chuang, P. E. Clark, S. D. Cramer, K. Lohman, and J. J. Hu The ADPRT V762A Genetic Variant Contributes to Prostate Cancer Susceptibility and Deficient Enzyme Function Cancer Res., September 1, 2004; 64(17): 6344 - 6348. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
